

#8156
2/27/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: RUBEN et al.

Atty. Docket No. PZ003P4

Application Serial No.: 09/852,659

Group Art Unit: 1632

Filed: May 11, 2001

Examiner: Pappu, Sita S.

Title: **28 Human Secreted Proteins**



INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AQ cited on the attached Form PTO/SB/08A. Copies of references AA-AQ were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/152,060 filed September 11, 1998 to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the above-listed files for copies of references AA-AQ.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of

the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Date: February 15, 2002


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (phone)

Enclosures
JMM/DAS/lcc